Close

BioLineRx (BLRX) Announces CE Mark for BL-5010 as Treatment for Non-Surgical Removal of Skin Lesions

April 4, 2016 7:03 AM EDT Send to a Friend
BioLineRx Ltd. (Nasdaq: BLRX) announced that its partner, Omega Pharma, now part of Perrigo, has received CE Mark approval for ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login